Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing

NCT07462533 | Not Yet Recruiting Phase 2

• 1 other identifier: Pavise-IIT-2026
• Study Type: interventional
• Target: 8
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary objective of this study is to evaluate the efficacy and tolerability of Pavise Extracellular Matrix Restore (ECMR), compared with standard acute post-operative care, when used as the primary occlusive treatment immediately following ablative CO₂ and Er:YAG facial laser resurfacing to support wound healing.

Conditions

Skin Laxity

Keywords

face; rejuvenation; wrinkles; texture

Outcome Measures

Primary Outcomes (1)

• Investigator Evaluation of Erythema, Edema, Exudation and Crusting

  Circle one for Perioral Area: Erythema: 0= None 1. Mild 2. Moderate 3. Pronounced 4. Severe Edema: 0= None 1. Mild 2. Moderate 3. Pronounced 4. Severe Crusting: 0= None 1. Mild 2. Moderate 3. Pronounced 4. Severe Exudation: 0= None 1. Mild 2. Moderate 3. Pronounced 4. Severe Circle one for Periorbital Area: Erythema: 0= None 1. Mild 2. Moderate 3. Pronounced 4. Severe Edema: 0= None 1. Mild 2. Moderate 3. Pronounced 4. Severe Crusting: 0= None 1. Mild 2. Moderate 3. Pronounced 4. Severe Exudation: 0= None 1. Mild 2. Moderate 3. Pronounced 4. Severe

  Day of procedure, post day 1, post day 4, post day 7, post day 14

Secondary Outcomes (6)

• Fitzpatrick Goldman Classification of Wrinkling and Degree of Elastosis Scale

  Screening, Baseline, 3 month visit

• Tolerability Assessment by the Investigator

  Day of procedure, post day 1, post day 4, post day 7, post day 14, 3 month visit

• Subject Self Assessment Questionnaire

  Day of procedure, post day 1, post day 4, post day 7, post day 14, 3 month visit

• Subject Healing Questionnaire

  post day 1, post day 4, post day 7, post day 14

• Subject End of Study Self Assessment Questionnaire

  3 month visit

Study Arms (2)

Group A

SHAM COMPARATOR

4 participants will undergo an ablative CO₂ and Er:YAG facial laser resurfacing treatment and receive Pavise ECMR (extracellular matrix restore) serum for post treatment care.

Drug: Pavise Serum; Device: Co2/Er:YAG

Group B

ACTIVE COMPARATOR

4 participants will undergo an ablative CO₂ and Er:YAG facial laser resurfacing treatment and receive vehicle serum for post treatment care.

Drug: Sham Comparator; Device: Co2/Er:YAG

Interventions

Pavise Serum DRUG

Pavise ECMR (extracellular matrix restore) serum regimen combined with laser treatment

Group A

Sham Comparator DRUG

Vehicle serum regimen combined with laser treatment

Group B

Co2/Er:YAG DEVICE

Ablative laser resurfacing treatment

Group A; Group B

Eligibility Criteria

• Age: 35 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or females in good general health age 35-70 years of age.
• Subjects with score Moderate to Severe (Class II-III, Score 4-9) on the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale (Appendix E)
• Subjects with score Moderate to Severe facial photodamage as assessed by the Modified Griffth's Scale (Appendix F)
• Fitzpatrick skin types I-III.
• Must be willing to give and sign Informed Consent Form, Photography Release Form and HIPAA Form.
• The subject must be planning to undergo ablative CO2 and Er:YAG laser resurfacing to the face and willing to comply with study dosing and complete the entire course of the study.
• Subjects using any skin care products (per physician-investigator discretion) must discontinue use of these products 14 days before treatment and throughout the duration of the study. Subjects will only use the products they are instructed to use by the investigator.
• Male subjects with facial hair must be willing to shave the morning of the procedure
• Female patients will be either of non-childbearing potential defined as: Having no uterus or no menses for at least 12 months. Women of childbearing potential must agree to use an effective method of birth control during the study, such as:
• Hormonal contraception - pill, injection, implant, patch, vaginal ring, Intrauterine device
• Intrauterine coil
• Bilateral tubal ligation
• Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)
• Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active).
• Vasectomized partner (Must agree to use barrier method described above (4) if becomes sexually active with an Un-Vasectomized partner).

You may not qualify if:

• Pregnant, planning to become pregnant during the course of the study, or breastfeeding.
• Prescence of an active bacterial, fungal, or viral infection in the treatment area.
• Significant history or current evidence of a medical, psychological or other condition that, in the investigator's opinion, would preclude enrollment into the study.
• Use of any topical products containing tretinoins or derivatives, alpha-hydroxy acids, salicylic acid, and vitamins C or E (includes derivatives thereof) on the face within 14 days prior to or during the study period, other than the study products.
• Receipt of a chemical peel, any systemic steroids, a non-ablative laser, ablative laser, microfocused ultrasound, light or radio frequency treatment, deep chemical peel, or dermabrasion on their face within 6 months prior to study enrollment.
• Receipt of a microdermabrasion (light or medium skin peel) treatment to the face within 30 days prior to enrollment and unwillingness to refrain from use for the duration of the study period.
• Excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days prior to enrollment.
• Prior treatment with a systemic retinoid within the past 3 months (e.g., Accutane®, Roche Dermatologics).
• History of keloids or hypertrophic scars.
• Known allergy to Valacyclovir or Fluconazole or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-amino benzoic acid), or other local anesthetics of the amide or ester family sedation medication.
• Presence of tattoo and/or scar in the treatment area that in the investigator's opinion would interfere with study assessments.
• History of or the presence of any skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis) at the discretion of the physician-investigator
• Inability to comply with all study protocol restrictions and visits.
• Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
• History of non-compliance with clinical research protocols.

Sponsors & Collaborators

• Goldman, Butterwick, Fitzpatrick and Groff: lead
• Bai Biosciences: collaborator

MeSH Terms

Conditions

Cutis Laxa; Facies

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

West Dermatology Research Center

CONTACT

858-657-1004; research@clderm.com

Andrea Pacheco

CONTACT

apacheco@clderm.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: All subjects will receive on ablative laser facial treatment then be assigned to one of two groups for post treatment regimen.

Study Record Dates

• First Submitted: March 5, 2026
• First Posted: March 10, 2026
• Study Start: March 20, 2026
• Primary Completion: July 30, 2026
• Study Completion (Estimated): August 30, 2026
• Last Updated: March 10, 2026

Record last verified: 2026-03